Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Glioma trials
The registry lists 28 Glioma studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 19Phase 2 9No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 MutationsCompletedNCT03914742Phase 1/2Results posted
- Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic GliomaCompletedNCT00058123Phase 2Results posted
- Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to ApixabanTerminatedNCT04895553
- Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade GliomasTerminatedNCT03971734Phase 1
- Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing GliomaTerminatedNCT03843814Not applicable
- A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent GliomasTerminatedNCT03593993
- Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade GliomasTerminatedNCT02659800Phase 1
- Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain TumorsCompletedNCT02644291Phase 1
- Terameprocol in Treating Patients With Recurrent High Grade GliomaCompletedNCT02575794Phase 1
- Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade GliomasCompletedNCT02041611Not applicable
- Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving TemozolomideCompletedNCT01729260Phase 1
- Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).CompletedNCT01688401Phase 1
- Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent GliomaCompletedNCT01480050Phase 1
- Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant GliomaCompletedNCT00897611Not applicable
- Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation TherapyTerminatedNCT00471653
- Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant GliomaCompletedNCT00401024Phase 1
- Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed GliomasCompletedNCT00095771Phase 1
- Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary GliomaCompletedNCT00027625Phase 1
- CCI-779 in Treating Patients With Malignant GliomaCompletedNCT00022724Phase 1/2
- Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or MeningiomaCompletedNCT00010049Phase 1/2
- Fenretinide in Treating Patients With Recurrent Malignant GliomaCompletedNCT00006080Phase 2
- Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant GliomaCompletedNCT00006025Phase 1
- Tipifarnib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00005859Phase 1/2
- SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation TherapyCompletedNCT00004868Phase 1/2
- Gene Therapy in Treating Patients With Recurrent Malignant GliomasCompletedNCT00004041Phase 1
- Irinotecan in Treating Patients With Progressive or Recurrent Malignant GliomaCompletedNCT00003616Phase 1/2
- Temozolomide and Carmustine in Treating Patients With Anaplastic GliomaCompletedNCT00003176Phase 2
- O(6)-Benzylguanine in Treating Patients With Malignant GliomaCompletedNCT00002971Phase 1